Drug Trial Radar · NCT07123428
Single and Multiple Ascending Doses and Food Effect Study of TRD205 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
151
Actual
Start
Jan 26, 2024
Primary completion
Nov 27, 2024
Study completion Feb 27, 2025
Sponsor
- Lead sponsor
- Beijing Tide Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of TRD205 after single and multiple doses and to evaluate the effect of food on TRD205 in healthy adult subjects.
Conditions
- Healthy
Interventions
TRD205Drug
TRD205 tablet
PlaceboDrug
TRD205 placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-Related Adverse EventsTime frame: After a single dose and/or once daily for 10 consecutive doses
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The first hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.